217 related articles for article (PubMed ID: 31834447)
1. Succinate detection using in vivo
Lussey-Lepoutre C; Bellucci A; Burnichon N; Amar L; Buffet A; Drossart T; Fontaine S; Clement O; Benit P; Rustin P; Groussin L; Meatchi T; Gimenez-Roqueplo AP; Tavitian B; Favier J
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1510-1517. PubMed ID: 31834447
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.
Lussey-Lepoutre C; Bellucci A; Morin A; Buffet A; Amar L; Janin M; Ottolenghi C; Zinzindohoué F; Autret G; Burnichon N; Robidel E; Banting B; Fontaine S; Cuenod CA; Benit P; Rustin P; Halimi P; Fournier L; Gimenez-Roqueplo AP; Favier J; Tavitian B
Clin Cancer Res; 2016 Mar; 22(5):1120-9. PubMed ID: 26490314
[TBL] [Abstract][Full Text] [Related]
3. SDHx mutation and pituitary adenoma: can in vivo 1H-MR spectroscopy unravel the link?
Branzoli F; Salgues B; Marjańska M; Laloi-Michelin M; Herman P; Le Collen L; Delemer B; Riancho J; Kuhn E; Jublanc C; Burnichon N; Amar L; Favier J; Gimenez-Roqueplo AP; Buffet A; Lussey-Lepoutre C
Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36449569
[TBL] [Abstract][Full Text] [Related]
4. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
5. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit.
Bancel LP; Masso V; Dessein AF; Aubert S; Leteurtre E; Coppin L; Odou MF; Cao CD; Cardot-Bauters C; Pigny P
J Clin Endocrinol Metab; 2023 Aug; 108(9):2343-2352. PubMed ID: 36848172
[TBL] [Abstract][Full Text] [Related]
6. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
[TBL] [Abstract][Full Text] [Related]
7. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
Baysal BE; Maher ER
Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
[TBL] [Abstract][Full Text] [Related]
8. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.
van Nederveen FH; Gaal J; Favier J; Korpershoek E; Oldenburg RA; de Bruyn EM; Sleddens HF; Derkx P; Rivière J; Dannenberg H; Petri BJ; Komminoth P; Pacak K; Hop WC; Pollard PJ; Mannelli M; Bayley JP; Perren A; Niemann S; Verhofstad AA; de Bruïne AP; Maher ER; Tissier F; Méatchi T; Badoual C; Bertherat J; Amar L; Alataki D; Van Marck E; Ferrau F; François J; de Herder WW; Peeters MP; van Linge A; Lenders JW; Gimenez-Roqueplo AP; de Krijger RR; Dinjens WN
Lancet Oncol; 2009 Aug; 10(8):764-71. PubMed ID: 19576851
[TBL] [Abstract][Full Text] [Related]
9.
Feral CC; Tissot FS; Tosello L; Fakhry N; Sebag F; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):812-821. PubMed ID: 27900521
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
[TBL] [Abstract][Full Text] [Related]
11. GROWTH RATE OF PARAGANGLIOMAS RELATED TO GERMLINE MUTATIONS OF THE SDHX GENES.
Michałowska I; Ćwikła JB; Michalski W; Wyrwicz LS; Prejbisz A; Szperl M; Nieć D; Neumann HP; Januszewicz A; Pęczkowska M
Endocr Pract; 2017 Mar; 23(3):342-352. PubMed ID: 27967220
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
Gill AJ; Benn DE; Chou A; Clarkson A; Muljono A; Meyer-Rochow GY; Richardson AL; Sidhu SB; Robinson BG; Clifton-Bligh RJ
Hum Pathol; 2010 Jun; 41(6):805-14. PubMed ID: 20236688
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
[TBL] [Abstract][Full Text] [Related]
14. Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline
Santi R; Rapizzi E; Canu L; Ercolino T; Baroni G; Fucci R; Costa G; Mannelli M; Nesi G
Anticancer Res; 2017 Feb; 37(2):805-812. PubMed ID: 28179334
[TBL] [Abstract][Full Text] [Related]
15. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
16. Risk of metastatic pheochromocytoma and paraganglioma in
Lee H; Jeong S; Yu Y; Kang J; Sun H; Rhee JK; Kim YH
J Med Genet; 2020 Apr; 57(4):217-225. PubMed ID: 31649053
[TBL] [Abstract][Full Text] [Related]
17. Master regulator analysis of paragangliomas carrying SDHx, VHL, or MAML3 genetic alterations.
Smestad JA; Maher LJ
BMC Cancer; 2019 Jun; 19(1):619. PubMed ID: 31234811
[TBL] [Abstract][Full Text] [Related]
18. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
[TBL] [Abstract][Full Text] [Related]
19. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
[TBL] [Abstract][Full Text] [Related]
20. Variant type is associated with disease characteristics in SDHB, SDHC and SDHD-linked phaeochromocytoma-paraganglioma.
Bayley JP; Bausch B; Rijken JA; van Hulsteijn LT; Jansen JC; Ascher D; Pires DEV; Hes FJ; Hensen EF; Corssmit EPM; Devilee P; Neumann HPH
J Med Genet; 2020 Feb; 57(2):96-103. PubMed ID: 31492822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]